Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chickenpox Vaccine
Oka/GSK attenuated varicella vaccine prevents chickenpox
July 24th, 2005
The Oka/GSK attenuated varicella vaccine was effective for the prevention of chickenpox in clinical practice in Israel. According to a study from Israel, "The varicella Oka/Merck vaccine has been shown to be very effective in clinical practice; however, several recent studies reported reduced effectiveness. The varicella Oka/GSK vaccine, which has been subjected to fewer effectiveness studies, was licensed in Israel for voluntary use in 2000. "This study was planned to estimate the effectiveness of the varicella Oka/GSK vaccine among children 1-5 years of age. Recent reports of varicella were retrieved from the Tel Aviv Health District." ...
Source: Medical Letter on the CDC & FDA (2005-07-24)
|
